Skip to Content
Søg Menu

Adjuvant pembrolizumab for resected high-risk stage melanoma decreased the risk of death

In this MEDtalk Jason Luke, associate professor, presents the results from KEYNOTE-716 study, where patients with high-risk stage melanoma were treated with pembrolizumab (pembro) versus placebo in pts with resected AJCC-8 stage IIB or IIC melanoma

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

The Ultimate Proof That Immunotherapy Can Be Curative for Metastatic Malignant Melanoma

/ BestPractice Nordic
ESMO24Melanom
Rasmus Friis

Fejring af langtidsdata for behandling af metastatisk malign melanom – og døren til neoadjuverende behandling er ved at åbne sig

/ Rasmus Blechingberg Friis
ESMO24Melanom Play the Video 09:51
Marco Donia

Significant Updates on Neoadjuvant Treatments for Stage 3 Melanoma

/ Marco Donia
ESMO24MelanomImmunterapi Play the Video 4:39
Hildur Helgadottir

The Effect of Adjuvant Treatment on Overall Survival in Melanoma Stage III Patients

/ Hildur Helgadottir
ESMO24Melanom Play the Video 6:50
Hanna Grauers Wiktorin

Objective Responses and Stable Disease in Patients with Immunotherapy Refractory Advanced Malignant Melanoma

/ Hanna Grauers Wiktorin
ESMO24Melanom Play the Video 07:24
Marco Donia

ESMO 2023 Highlights: Developments in Melanoma

/ Marco Donia
ESMO23Melanom Play the Video 03:46

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
ASCO23Melanom

Adjuvant Pembrolizumab Continue to Demonstrate Significant Improvements for Patients with Stage IIB/IIC Melanoma

/ BestPractice Nordic
ASCO23Melanom
Back to top